---
title: "Lysergide (DT120) in Generalized anxiety disorder: Indication"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Indication. Topics: Indication under development: adults with generalized anxiety disorder, Population studied in the phase 3 Panorama trial, Labeling scope sought and filing strategy across generalized anxiety disorder and major depressive disorder, and Other indications in development: major depressive disorder and posttraumatic stress disorder. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/indication"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Indication under development: adults with generalized anxiety disorder

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”
> “The primary endpoint for each trial is the change from baseline on the Hamilton Anxiety Rating Scale (“HAM-A”) at Week 12 between DT120 ODT 100 µg and placebo.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

### Population studied in the phase 3 Panorama trial

> “The study enrolled participants 18 to 74 years of age with a DSM-5-confirmed primary diagnosis of GAD and a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of 20 at screening and baseline.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.5-3"></a>

### Labeling scope sought and filing strategy across generalized anxiety disorder and major depressive disorder

> “Robust Phase 3 DT120 ODT Development Program Aiming for Broad Label”
> “Regulatory filing strategy for GAD & MDD to be discussed at pre-NDA meeting.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.5-4"></a>

### Other indications in development: major depressive disorder and posttraumatic stress disorder

> “Continuing enrollment for the Phase 3 Ascend study in MDD.”
> “DT120 ODT in PTSD: Planning to initiate the Phase 3 Haven study in PTSD in 2027 with approximately 200 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.2.5-5"></a>

### Proposed labeled indication submitted to a regulator

No evidence found.

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
